AX-2025-020123
MGF · 5 mg declared · Shanghai ERP Biotechnology Co., Ltd. · lot ERP-2501-B8503
- Report ID
- AX-2025-020123
- Compound
- MGF
- Compound class
- Growth-hormone axis peptides
- Supplier
- ERP — Shanghai ERP Biotechnology Co., Ltd.
- Batch / lot
- ERP-2501-B8503
- Declared label claim
- 5mg
- Laboratory
- Janoshik Analytical
- Assay date
- 12 Mar 2025
- Submitted
- 04 Apr 2025
- Quarter
- 2025-Q1
- Submitter
- ka.castellanos
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 98.51 | % area | ≥ 97.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.49 | % area | ≤ 2.5 | PASS |
| Largest single impurity | RP-HPLC — aspartimide (−18 Da) | 0.88 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 2886.5117 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 2886.5114 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -0.1 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 91.16 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.80 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 5.18 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 4.652 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 93.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 3.08 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.15 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.61 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White cake, partially collapsed | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.32 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 11.56 | min | 11.62 ± 0.30 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.16 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 72,054 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs deamidated (+1 Da) | 1.36 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | MGF — main peak | 11.56 | 4,787,891 | 98.51 | — |
| 2 | aspartimide (−18 Da) | 11.88 | 42,771 | 0.88 | -18.011 |
| 3 | truncated (1-20) | 10.34 | 20,413 | 0.42 | -486.271 |
| 4 | acetyl adduct (+42 Da) | 11.96 | 4,860 | 0.10 | +42.011 |
| 5 | deamidated (+1 Da) | 11.32 | 4,374 | 0.09 | +0.984 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 2886.5117 Da, computed from C121H200N42O37. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 5+ | 578.3096 | 578.3096 | -0.0000 | 9.0 |
| 4+ | 722.6352 | 722.6351 | -0.0001 | 58.0 |
| 3+ | 963.1778 | 963.1777 | -0.0001 | 100.0 |
| 2+ | 1444.2631 | 1444.2630 | -0.0001 | 52.7 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 3.08 |
| Counter-ion (acetate) | ion chromatography | 5.15 |
| Residual solvent + inorganic residue | estimated | 0.61 |
| Total peptide content | by difference | 91.16 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.63 | 98.51 | divergence +0.78 pp vs batch median |
| Total impurities (% area) | 0.37 | 1.49 | |
| Largest single impurity (% area) | 0.18 | 0.88 | |
| Water (%) | 0.6 | 3.08 | |
| Counter-ion (%) | not stated | 5.15 | |
| Peptide content (%w/w) | not stated | 91.16 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (2–8 °C, 19 d) → laboratory (courier, ambient, 11 d) → assay.
- Assay date
- 12 Mar 2025
- Submitted to the index
- 04 Apr 2025
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot ERP-2501-B8503 n=2
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-020122 | ERP-2501-B8503 | Kestrel | 2025-Q1 | 99.19 | 2.88 | — | Buyer-sourced | 0 | PASS |
Cross-sections
- All MGF records n=37
- All ERP records n=205
- All Janoshik records n=2989
- All 2025-Q1 records n=672
- MGF by supplier
- MGF impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043660 | PPG | PPG-2512-G7713 | Janoshik | 2026-Q2 | 99.30 | 4.25 | 95.8 | Buyer-sourced | 0 | PASS |
| AX-2026-043656 | PPG | PPG-2512-G7713 | PeptideMeter | 2026-Q2 | 99.09 | 4.22 | 99.3 | Buyer-sourced | 0 | PASS |
| AX-2026-043657 | PPG | PPG-2512-G7713 | Janoshik | 2026-Q2 | 99.06 | 4.25 | 107.0 | Buyer-sourced | 0 | PASS |
| AX-2026-043466 | BCH | BCH-2511-D5168 | Janoshik | 2026-Q2 | 99.04 | 5.33 | 103.5 | Buyer-sourced | 0 | PASS |
| AX-2026-043464 | BCH | BCH-2511-D5168 | VendorInvestigate | 2026-Q2 | 99.39 | 5.79 | 100.2 | Buyer-sourced | 0 | PASS |
| AX-2026-043655 | PPG | PPG-2512-G7713 | Medutest | 2026-Q2 | 99.03 | 4.14 | 99.6 | Buyer-sourced | 0 | PASS |
| AX-2026-043467 | BCH | BCH-2511-D5168 | Janoshik | 2026-Q2 | 99.46 | 5.95 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043652 | PPG | PPG-2512-G7713 | Janoshik | 2026-Q2 | 99.33 | 3.87 | 101.6 | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042706 | Survodutide | ERP-2605-E9865 | PeptideMeter | 2026-Q3 | 98.38 | 5.33 | 103.5 | Buyer-sourced | 0 | PASS |
| AX-2026-042704 | Tesamorelin | ERP-2604-W9463 | Janoshik | 2026-Q3 | 99.02 | 4.08 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042705 | Survodutide | ERP-2605-E9865 | Janoshik | 2026-Q3 | 98.24 | 5.36 | 92.3 | Buyer-sourced | 0 | PASS |
| AX-2026-042708 | GHK-Cu | ERP-2601-F9816 | Nordanalyt | 2026-Q2 | 98.88 | 3.87 | 91.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042694 | Liraglutide | ERP-2601-P8985 | Kestrel | 2026-Q2 | 99.25 | 4.35 | 107.3 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042707 | GHK-Cu | ERP-2601-F9816 | Janoshik | 2026-Q2 | 98.53 | 4.70 | 96.3 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042711 | GHK-Cu | ERP-2601-F9816 | Kestrel | 2026-Q2 | 98.53 | 3.84 | 89.7 | Laboratory-retained | 2 | MARGINAL |
| AX-2026-042722 | Tirzepatide | ERP-2512-T9616 | Medutest | 2026-Q2 | 99.18 | 2.07 | — | Buyer-sourced | 1 | MARGINAL |